Red Yeast Rice: Food, Drug, Or Both? - News

In June 2026, the European Food Safety Authority (EFSA) once again placed the safety assessment of monacolin K from red yeast rice (RYR) on its agenda. What appears to be a routine technical review conceals a far more profound question that has been simmering for over a decade: when a compound found in a traditional fermented food is chemically identical to a globally bestselling prescription drug, does it belong in the food category, the dietary supplement category, or the unapproved drug category?

This question has now evolved into a full‑blown global regulatory crisis spanning Europe, North America, and Asia.

Red Yeast Rice: Food, Drug, or Both?

A thousand‑year history meets 1970s pharmacology

Red yeast rice - rice fermented with Monascus purpureus - has been used in China for over a thousand years as both a food colourant and a medicinal ingredient, described across a long lineage of Chinese medical and dietary literature as aiding digestion and blood circulation.

In 1979, Japanese microbiologist Akira Endo isolated an active compound capable of inhibiting cholesterol synthesis from Monascus ruber, naming it monacolin K. Endo's landmark paper, published in The Journal of Antibiotics, described the isolation, physical and chemical properties, and hypocholesterolemic effects of this new compound.

Working separately and in the same year, scientists at the U.S. pharmaceutical company Merck isolated a structurally related compound from Aspergillus terreus - a compound they named mevinolin. By the autumn of 1979, it was confirmed that monacolin K and mevinolin were the same molecule, later renamed lovastatin. Merck's lovastatin received FDA approval in 1987 as one of the first statin drugs, launching a new era in cardiovascular medicine.

Chemical identity: one molecule, two origins

Lovastatin

Monacolin K's chemical formula - C₂₄H₃₆O₅ - is identical to that of lovastatin. From a chemical standpoint, they are the same molecule. The only difference lies in their origin: monacolin K is biosynthesised through the secondary metabolic pathway of Monascus fungi, while lovastatin was originally isolated from Aspergillus terreus fermentation and later produced through chemical or semi‑synthesis for industrial manufacture.

This chemical identity lies at the heart of the regulatory dilemma: the same molecule exists simultaneously in a traditional food and a prescription drug. Its legal status depends on content, intended use, and regulatory framework - not on the molecule itself.

Commercially available red yeast rice products vary enormously in monacolin K content, with typical concentrations ranging from 2 to 10 mg per gram, while some potency‑enhanced products may exceed 15 mg per gram. At a recommended daily intake of 3 to 10 mg, this falls squarely within the clinical therapeutic window of lovastatin (10 to 80 mg/day). Consumers ingesting a daily red yeast rice supplement may be exposed to pharmacologically active doses equivalent to low‑dose prescription statins.

The regulatory rift: three markets, three paths

European Union: the strictest regime

In 2018, EFSA's Panel on Food Additives and Nutrient Sources (ANS) concluded that serious adverse effects could occur even at low intake levels. In 2022, monacolins from red yeast rice were placed under Union scrutiny in Part C of Annex III of Regulation (EC) No 1925/2006, reducing the maximum permitted amount to less than 3 mg/day and mandating warning labels.

On 29 January 2025, EFSA's Panel on Nutrition, Novel Foods and Food Allergens (NDA) adopted a scientific opinion reviewing additional data submitted during the scrutiny period. The NDA Panel reiterated the ANS Panel's concerns that exposure to monacolin K from RYR at intake levels as low as 3 mg/day could lead to severe adverse effects on the musculoskeletal system, including rhabdomyolysis, and on the liver. The Panel concluded that the data submitted did not allow establishing the safety of monacolins in RYR supplements below 3 mg/day, nor identify a daily intake that does not raise safety concerns.

In subsequent safety studies, EFSA concluded that monacolins are not safe at any dose and therefore intends to prohibit their use by including them in Part A (prohibited substances) of Annex III of Regulation (EC) No 1925/2006.

On 13 May 2026, EU Member States voted in favour of the draft regulation banning monacolins derived from red yeast rice. The European Commission is now likely to move monacolins from red yeast rice into Part A of Annex III, with the final regulation expected around the middle of 2026. Multiple EU member states, including Ireland, Denmark, Sweden, and Belgium, have already imposed restrictions or outright bans on RYR supplements containing monacolin K.

"I don't see how this consultation at the WTO level will change the draft regulation," said Dr Jerome Le Bloch, head of scientific affairs at Foodchain ID.

United States: the dietary supplement grey zone

In the United States, red yeast rice products are classified as dietary supplements under the Dietary Supplement Health and Education Act (DSHEA) of 1994. Safety is the responsibility of manufacturers, with the FDA exercising post‑market enforcement.

The FDA's position has been that if a product contains a compound that is already an approved drug, and is being marketed for therapeutic effect - such as lowering cholesterol - then it falls under drug regulation. In one of the earliest and most important tests of DSHEA's "drug preclusion" clause, the FDA challenged dietary supplement company Pharmanex in 1997 after finding that its Cholestin product contained significant levels of monacolin K. The agency argued that this made Cholestin an unapproved drug and ordered Pharmanex to stop marketing it as a dietary supplement.

Since then, the FDA has issued multiple warning letters to red yeast rice supplement manufacturers, advising that products containing monacolin K effectively constitute unapproved new drugs and cannot be marketed with cholesterol‑lowering claims. However, FDA actions have been case‑by‑case, lacking a systematic regulatory stance. As a result, numerous products continue to circulate with vague claims such as "supports cardiovascular health" and "helps maintain normal cholesterol levels."

The FDA has also noted that testing for adulteration in RYR supplements is challenging because monacolin K and lovastatin are chemically identical but derived from different sources.

China: the dilemma of balancing tradition and modernisation

As the country of origin and a traditional consumer of red yeast rice, China feels the tension of this dual identity most acutely. Functional red yeast rice (containing monacolin K at ≥0.4%) is regulated as a health food in China, requiring registration or filing with the State Administration for Market Regulation and subject to review of function claims. Meanwhile, ordinary red yeast rice (with low monacolin K content) circulates largely unrestricted as a food ingredient.

However, the classification of imported RYR supplements - whether as food imports, health food registrations, or pharmaceutical products - has long lacked a unified standard in practice. A 2026 critical narrative review in Molecules detailed the current applications of RYR in functional foods, dietary supplements, and traditional fermented products, alongside a comparison of the divergent regulatory frameworks for RYR across major global markets.

Red Yeast Rice Extract Powder

The deeper logic: dose makes the drug

The crisis reveals a fundamental gap in global regulatory systems: the failure to adequately address the pharmacological principle that "the dose makes the poison" when it comes to natural products.

From the perspective of natural product chemistry, the red yeast rice case is far from unique. Triptolide - found in the traditional Chinese medicine Tripterygium wilfordii - possesses immunosuppressive activity potent enough to rival prescription drugs. Artemisinin - isolated from the Chinese herb Artemisia annua - has been listed by the WHO as a first‑line antimalarial drug. These cases all point to a single truth: natural products are not inherently safe. Their safety depends on dose, conditions of use, and regulatory oversight - not on their natural origin.

What this means for the nutraceutical industry

For the global natural products industry, the current fragmentation creates tangible commercial and compliance risks. The EU's strict restrictions have compressed export markets for RYR supplements, while the US's more permissive approach leaves consumers exposed to statin use without medical supervision. Potential drug interactions - particularly with CYP3A4 substrate drugs that share metabolic pathways with statins - and the absence of adverse event monitoring mean that the "natural cholesterol‑lowering" marketing tagline conceals safety concerns that cannot be ignored.

Dr Miguel Florido, a nutraceutical formulation consultant specialising in cardiometabolic health, noted that monacolins will leave a large therapeutic gap, as they have been one of the most effective lipid‑lowering nutraceuticals because they function similarly to a statin. Current alternatives include bergamot polyphenols and berberine - although berberine is also under safety review by EFSA.

Conclusion: finding a regulatory path forward

The story of red yeast rice and monacolin K is far from over. In 2026, EFSA, the FDA, and Chinese regulators continue to fine‑tune their respective positions, but fundamental regulatory coordination has yet to emerge.

From the perspective of natural product chemistry, resolving this dilemma may require establishing a "pharmacological equivalence" principle: whenever exposure to an active ingredient in a natural product reaches or exceeds a known therapeutic threshold, the product should be subject to the pharmaceutical regulatory framework for safety assessment and pre‑market review - regardless of whether the active ingredient is synthetic or biosynthetic.

Only through such an approach can a regulatory path be forged for "food‑as‑medicine" natural products that respect both tradition and public health.

Nature does not distinguish between food and medicine. Human legal definitions do. When the chemical identity is the same, our regulatory frameworks must have the capacity to confront this reality.

Contact now

References

⚠️ Important Disclaimer

The information provided in this article is for educational and informational purposes only and is not intended as medical advice. It does not replace professional medical consultation, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition or before starting any new supplement regimen. The products and ingredients mentioned are not intended to diagnose, treat, cure, or prevent any disease.